ADC Therapeutics S.A.
ADCT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $545,786 | $304,832 | $151,155 | $209,739 |
| - Cash | $0 | $264,560 | $194,701 | $250,867 |
| + Debt | $0 | $117,523 | $456,814 | $122,998 |
| Enterprise Value | $545,786 | $157,795 | $413,268 | $81,870 |
| Revenue | $16,427 | $18,839 | $23,033 | $16,910 |
| % Growth | -12.8% | -18.2% | 36.2% | – |
| Gross Profit | $15,225 | $18,003 | $20,972 | $15,539 |
| % Margin | 92.7% | 95.6% | 91.1% | 91.9% |
| EBITDA | -$27,452 | -$41,555 | -$25,687 | -$18,832 |
| % Margin | -167.1% | -220.6% | -111.5% | -111.4% |
| Net Income | -$40,966 | -$56,646 | -$38,602 | -$30,727 |
| % Margin | -249.4% | -300.7% | -167.6% | -181.7% |
| EPS Diluted | -0.3 | -0.5 | -0.36 | -0.29 |
| % Growth | 40% | -38.9% | -24.1% | – |
| Operating Cash Flow | -$29,630 | -$24,087 | -$56,334 | -$21,852 |
| Capital Expenditures | $0 | $0 | -$264 | -$90 |
| Free Cash Flow | -$29,630 | -$24,087 | -$56,598 | -$21,942 |